Celularity Inc
CELU Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.75
KIRA · Stoqly’s AI analyst, in plain words
- Celularity Inc had $26.6M of revenue in fiscal 2025, down 51.0% on the year before. Over five years, revenue changed +13.2% a year on average.
- Its operating margin was −230.9%, down 160.2 pts: of every 100 in sales, about −231 is left after running the business.
- Celularity Inc lost $91.7M in fiscal 2025.
- Celularity Inc owes $27.6M more than it holds in cash.
Market cap
$22.0M
P/E
—
Revenue
$26.6M
Net income
−$91.7M
Free cash flow
—
Operating margin
−230.9%
Celularity Inc in 30 seconds · fiscal 2025
Are sales growing?
−51.0%
No. Sales fell 51.0% last year.
Does it make a profit?
−345.4%
No. It lost money last year.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Celularity Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 30, 2026
- Legal name
- Celularity Inc
- CIK
- 0001752828
Celularity Inc · CELU
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $21.3M | $18.0M | $22.8M | $54.2M | $26.6M |
| Revenue growth | 49.4% | −15.7% | 26.7% | 138.1% | −51.0% |
| Gross margin | 54.8% | −9.4% | 29.7% | 72.4% | 24.4% |
| Operating margin | −511.2% | −142.4% | −844.4% | −70.7% | −230.9% |
| Net income | −$100M | $14.2M | −$196M | −$57.9M | −$91.7M |
| Net margin | −469.3% | 79.0% | −862.0% | −106.8% | −345.4% |
| Diluted EPS | −$1.49 | $0.95 | −$11.02 | −$2.64 | −$3.59 |
| Cash | |||||
| Cash from operations | −$110M | −$138M | −$38.7M | −$6.4M | −$13.3M |
| Capital expenditure | $6.2M | $5.2M | $1.0M | $0.2M | — |
| Free cash flow | −$116M | −$143M | −$39.7M | −$6.6M | — |
| FCF margin | −545.1% | −796.2% | −174.5% | −12.1% | — |
| Share count change | 264.1% | −77.7% | 18.9% | 22.9% | 16.9% |
| Debt and strength | |||||
| Cash and short-term investments | $37.2M | $14.0M | $0.2M | $0.7M | $6.2M |
| Debt incl. finance leases | — | $37.6M | $17.2M | — | $33.8M |
| Shareholders' equity | $99.4M | $199M | $41.0M | $8.8M | −$38.1M |
| Current ratio | 2.3x | 0.5x | 0.3x | 0.4x | 0.2x |
| Returns and quality | |||||
| Return on capital | — | −11.5% | −262.1% | — | — |
| Return on equity | — | 9.5% | −163.7% | −232.5% | — |
| Return on tangible equity | — | — | −868.1% | — | — |
| Piotroski F-score | 2 | 3 | 3 | 5 | 1 |
| Altman Z'' | −6.1 | −5.1 | −29.8 | −25.6 | −38.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Celularity Inc · CELU
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.75 a share, the company is worth $22.0M.
Source: SEC EDGAR XBRL filings (CIK 0001752828). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.